Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
It also slows down gastric emptying, or the emptying of your stomach, leaving you with a sense that youre full
Potential increased risk of thyroid cancer
NSL literature pointer PMID 30149425 L-Carnitine laboratory index [PMID: 30149425] National Science Labs indexing note for PMID 30149425: review the PubMed methods, models, and limitations before citing
Challenges include side effects, lack of insurance coverage for off-label conditions and high out-of-pocket costs
